2025 Volume 51 - Canada Communicable Disease Report (CCDR)

ISSN: 1481-8531

2025 Volume 51

CCDR Volume 51-8, August 2025: Antiviral Therapy

• Summary of the National Advisory Committee on Immunization (NACI) statement on the prevention of respiratory syncytial virus (RSV) in older adults
• Evaluation of a real-time hospital surveillance system for respiratory syncytial virus, Ontario, Canada, 2022–2023
• Implementation of the COVID-19 antiviral therapy Nirmatrelvir/Ritonavir (Paxlovid^TM) across Canada in 2022: A qualitative analysis of key facilitating factors and challenges
• Effectiveness of the four-component protein-based meningococcal vaccine against Neisseria gonorrhoeae infections: Mounting evidence and public health implications for Canada
• Safety monitoring of Imvamune vaccine during the 2022 mpox outbreak in Canada

CCDR Volume 51-6/7, June/July 2025: Hepatitis B & C Viruses in Canada

• Estimated prevalence of hepatitis B and C among immigrants in Canada
• National hepatitis B and C estimates for 2021: Measuring Canada's progress towards eliminating viral hepatitis as a public health concern
• Prevalence and awareness of hepatitis B and hepatitis C and vaccine-induced immunity to hepatitis B: Findings from the Canadian Health Measure Survey, 2016–2019
• Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2019–2023
• Device and surgical procedure-related infections in Canadian acute care hospitals, 2019–2023
• Ten years of Foodbook: Utilization of Foodbook survey data for research

CCDR Volume 51-5, May 2025: Travel Health

• A Science Strategy for the Public Health Agency of Canada
• Assessing the impact of the COVID-19 pandemic on trends of select travel-acquired enteric illnesses in Canada
• Enhanced screening for tuberculosis infection among immigrants in southern New Brunswick: A cross-sectional pilot study
• Cutaneous larva migrans in Canadian travellers returning from the Caribbean: A 10-year surveillance analysis from CanTravNet
• Acute histoplasmosis in four immunocompetent Canadian travellers to a cenote in Yucatán, Mexico
• Proposed approaches for public health surveillance: A literature review for the Canadian National HIV Surveillance Program
• Travel-related dengue, Zika and chikungunya in Canada, 2012–2023: Results from a feasibility pilot study on laboratory-based surveillance
• Retro 3: A feasibility pilot study for the development of a laboratory-based surveillance system for vector-borne diseases

CCDR Volume 51-4, April 2025: Challenges in Managing Gonorrhea and Prevention

• Summary of the National Advisory Committee on Immunization (NACI) Statement on the Prevention of Respiratory Syncytial Virus (RSV) in Infants
• Environmental scan of available guidelines for chlamydia and gonorrhea screening recommendations for non-pregnant adolescents/adults in developed countries
• Antimicrobial susceptibilities of Neisseria gonorrhoeae in Canada, 2022
• A rapid review of the avian influenza PB2 E627K mutation in human infection studies
• Associations between self-reported SARS-CoV-2 infection status, serology and common longer-term COVID-19 symptoms among adults in Canada, a cross-sectional study
• Screening of retail milk in Ontario for the presence of influenza A viral RNA
• Tips for Safely Handling Backyard Flock Eggs

CCDR Volume 51-2/3, February/March 2025: Health Economics in Public Health

• Cost-effectiveness of respiratory syncytial virus vaccination strategies for older Canadian adults: A multi-model comparison
• Comparison of 13-, 15- and 20-valent pneumococcal conjugate vaccines in the paediatric Canadian population: a cost-utility analysis
• Cost effectiveness of a 21-valent pneumococcal conjugate vaccine in adults: A systematic review of economic evaluations
• Public Health Risks Associated with Dog Importation
• Summary of the mpox outbreak in Canada, April 28−December 31, 2022
• Differences in sensationalism in international news media reporting of COVID-19: An exploratory analysis using the Global Public Health Intelligence Network (GPHIN) system
• Infectious syphilis and congenital syphilis in Canada, 2023

CCDR Volume 51-1, January 2025: Personal Protective Measures

• Summary of the National Advisory Committee on Immunization (NACI) Statement—Updated guidance on Imvamune in the context of a routine immunization program
• Is there sufficient evidence to inform personal protective equipment choices for healthcare workers caring for patients with viral hemorrhagic fevers?
• Surveillance of laboratory exposures to human pathogens and toxins, Canada, 2023
• Burden of disease of respiratory syncytial virus in older adults and adults considered at high risk of severe infection
• The prevalence of HIV pre-exposure prophylaxis (HIV-PrEP) use and HIV-PrEP-to-need ratio in nine Canadian provinces, 2018–2021
• Using behavioural science to improve antibiotic stewardship in Canadian long-term care homes: Protocol for a multi-center cluster randomized quality improvement study